Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.57
-1.3%
$25.41
$16.54
$28.13
$379.71M0.7679,088 shs12,867 shs
Profound Medical Corp. stock logo
PROF
Profound Medical
$7.80
-2.4%
$8.31
$7.11
$15.49
$190.55M0.840,208 shs3,249 shs
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$8.07
-5.8%
$15.08
$8.01
$21.70
$207.48M1.33210,040 shs88,998 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$25.56
-2.0%
$29.00
$16.79
$39.41
$363.97M1.0157,980 shs5,675 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
+0.43%+0.82%+3.23%+7.16%-3.00%
Profound Medical Corp. stock logo
PROF
Profound Medical
+3.77%+2.30%-1.48%-3.50%-30.40%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-4.57%-8.64%-45.98%-48.74%-38.08%
Surmodics, Inc. stock logo
SRDX
Surmodics
-3.16%-1.70%-4.99%-24.85%+9.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
3.1796 of 5 stars
2.31.00.03.61.91.71.9
Profound Medical Corp. stock logo
PROF
Profound Medical
1.6595 of 5 stars
3.52.00.00.02.40.80.6
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
0.931 of 5 stars
3.42.00.00.01.10.00.6
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1734 of 5 stars
3.52.00.03.42.31.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5015.37% Upside
Profound Medical Corp. stock logo
PROF
Profound Medical
3.00
Buy$14.5886.97% Upside
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
2.80
Moderate Buy$27.80244.49% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$59.00130.83% Upside

Current Analyst Ratings

Latest ANIK, SRDX, RCEL, and PROF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$22.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.00
2/23/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.00
2/23/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00
2/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $47.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.28$4.88 per share5.24$14.50 per share1.76
Profound Medical Corp. stock logo
PROF
Profound Medical
$7.20M26.47N/AN/A$1.28 per share6.09
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$50.14M4.14N/AN/A$1.92 per share4.20
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M2.75$0.74 per share34.33$8.48 per share3.01

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.65N/A18.942.30-49.60%-2.10%-1.71%5/8/2024 (Confirmed)
Profound Medical Corp. stock logo
PROF
Profound Medical
-$28.57M-$1.35N/AN/AN/A-396.85%-70.18%-53.80%5/9/2024 (Confirmed)
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.3867.26N/AN/A3.99%8.06%5.11%5/1/2024 (Confirmed)

Latest ANIK, SRDX, RCEL, and PROF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$0.26N/A+$0.26N/AN/AN/A  
5/9/2024N/A
Profound Medical Corp. stock logo
PROF
Profound Medical
-$0.31N/A+$0.31N/AN/AN/A
5/8/2024N/A
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.19N/A+$0.19N/AN/AN/A  
5/1/2024N/A
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36N/A+$0.36N/AN/AN/A  
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
3/7/2024Q4 2023
Profound Medical Corp. stock logo
PROF
Profound Medical
-$0.28-$0.42-$0.14-$0.42$1.90 million$2.01 million
2/22/2024Q4 2023
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Profound Medical Corp. stock logo
PROF
Profound Medical
N/AN/AN/AN/AN/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.26
3.76
Profound Medical Corp. stock logo
PROF
Profound Medical
0.16
6.58
5.48
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
0.81
7.88
7.46
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.84
3.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Profound Medical Corp. stock logo
PROF
Profound Medical
47.86%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
27.66%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
Profound Medical Corp. stock logo
PROF
Profound Medical
1.52%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
1.96%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.85 million13.98 millionOptionable
Profound Medical Corp. stock logo
PROF
Profound Medical
13124.43 million24.06 millionOptionable
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
20725.71 million25.20 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.24 million12.97 millionOptionable

ANIK, SRDX, RCEL, and PROF Headlines

SourceHeadline
Surmodics (SRDX) Set to Announce Quarterly Earnings on WednesdaySurmodics (SRDX) Set to Announce Quarterly Earnings on Wednesday
marketbeat.com - April 24 at 6:45 AM
Surmodics (NASDAQ:SRDX) Downgraded by StockNews.com to BuySurmodics (NASDAQ:SRDX) Downgraded by StockNews.com to Buy
americanbankingnews.com - April 24 at 2:22 AM
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM
Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"
americanbankingnews.com - April 17 at 3:42 AM
Surmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.comSurmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.com
marketbeat.com - April 16 at 11:04 PM
Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years
finance.yahoo.com - April 13 at 8:40 AM
Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 11 at 7:42 AM
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
markets.businessinsider.com - April 10 at 4:59 PM
Surmodics (SRDX) "Buy" Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) "Buy" Rating Reiterated at Needham & Company LLC
marketbeat.com - April 10 at 11:26 AM
Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 10 at 8:44 AM
New Strong Buy Stocks for April 9thNew Strong Buy Stocks for April 9th
zacks.com - April 9 at 7:16 AM
Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?
finance.yahoo.com - March 23 at 1:09 PM
Heres Why You Should Hold Surmodics (SRDX) Stock for NowHere's Why You Should Hold Surmodics (SRDX) Stock for Now
zacks.com - March 20 at 12:30 PM
Are Surmodics, Inc.s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?
finance.yahoo.com - March 2 at 1:31 PM
Surmodics to Participate in Upcoming Investor Conferences in March and AprilSurmodics to Participate in Upcoming Investor Conferences in March and April
businesswire.com - February 27 at 8:00 AM
SYK Jun 2024 290.000 putSYK Jun 2024 290.000 put
ca.finance.yahoo.com - February 6 at 1:03 PM
Heres What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter Results
finance.yahoo.com - February 4 at 9:23 AM
Heres Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.s (NASDAQ:SRDX) CEO Pay PacketHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay Packet
finance.yahoo.com - February 2 at 5:33 PM
Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - February 2 at 12:26 PM
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
finance.yahoo.com - February 2 at 12:26 PM
Surmodics Shares Decline 10% on Investors Lofty Expectations for SurVeilSurmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeil
marketwatch.com - February 1 at 5:53 PM
Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024
finance.yahoo.com - February 1 at 5:53 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Profound Medical logo

Profound Medical

NASDAQ:PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
AVITA Medical logo

AVITA Medical

NASDAQ:RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.